ADORA3 Gene
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">adora3</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ADORA3</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Adenosine A3 Receptor</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>A3AR, ADORA3, ADORA3, A3R</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1p13.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>128</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P0DP23</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000121879</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>G Protein-Coupled Receptor (GPCR)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Class A Rhodopsin-like</td>
</tr>
<tr>
<td class="label">Transcript Variants</td>
<td>3 principal isoforms</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">cAMP↓</td>
<td>Reduced PKA activity</td>
</tr>
<tr>
<td class="label">ERK1/2</td>
<td>Context-dependent</td>
</tr>
<tr>
<td class="label">p38 MAPK</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td class="label">Akt</td>
<td>Pro-survival</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Inhibited</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">I/II</td>
<td>CF101 (Cl-IB-MECA)</td>
</tr>
<tr>
<td class="label">I/II</td>
<td>CF102</td>
</tr>
<tr>
<td class="label">Preclinical</td>
<td>Novel agonists</td>
</tr>
<tr>
<td class="label">Protein/Pathway</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">Gi/o proteins</td>
<td>G protein coupling</td>
</tr>
<tr>
<td class="label">β-arrestin</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">GRK2/3</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">JNK3</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Akt</td>
<td>Downstream</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">4 edges</a></td>
</tr>
</table>
Overview
Mermaid diagram (expand to render)
ADORA3 (Adenosine A3 Receptor), also known as A3AR or ADORA3, encodes the adenosine A3 receptor, a member of the G protein-coupled receptor (GPCR) superfamily that plays critical roles in modulating cellular responses to adenosine in both peripheral tissues and the central nervous system["@fredholm2001"]. This receptor has emerged as a significant therapeutic target for neurodegenerative diseases due to its unique signaling properties and expression patterns in the brain["@borea2015"].
The adenosine A3 receptor is distinguished from other adenosine receptor subtypes (A1, A2A, A2B) by its ability to couple primarily to Gi/o proteins, leading to inhibition of adenylate cyclase and reduced cAMP production["@chen2013"]. This signaling pathway mediates diverse biological effects including modulation of neuroinflammation, protection against oxidative stress, regulation of autophagy, and preservation of neuronal viability under pathological conditions["@gessi2016"].
Protein Structure and Pharmacology
ADORA3 possesses the characteristic seven-transmembrane domain architecture common to all GPCRs[@fredholm2001]:
Structural Features
Seven transmembrane domains (TM1-TM7): Form the core of the receptor and mediate ligand binding
Extracellular loops (ECL1-ECL3): Contain glycosylation sites and contribute to ligand recognition
Intracellular loops (ICL1-ICL3): Couple to G proteins and contain regulatory phosphorylation sites
C-terminal tail: Contains serine/threonine residues for phosphorylation and β-arrestin recruitmentLigand Binding Properties
The adenosine A3 receptor exhibits distinct pharmacological characteristics:
- High affinity for adenosine: KD ≈ 1-10 nM for endogenous ligand
- Selective agonists: Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine), IB-MECA
- Selective antagonists: MRS1523 (3-propyl-6-ethyl-5-[(ethylamino)carbonyl]-2-phenylpyridine), VUF5574
- Allosteric modulators: Several allosteric binding sites have been identified
The receptor demonstrates species-dependent pharmacology, with notable differences between human and rodent A3 receptors that must be considered in preclinical drug development[@borea2015].
Signaling Pathways
Primary Signaling Mechanisms
ADORA3 mediates its effects through multiple interconnected signaling pathways[@gessi2016]:
Gi/o Protein-Coupled Signaling
Adenylate cyclase inhibition: Gi/o protein coupling reduces cAMP production
MAPK pathway modulation: ERK1/2, p38, and JNK pathways are affected
PI3K/Akt pathway: Involved in cell survival signaling
PLC activation: Some coupling to phospholipase C has been reportedβ-Arrestin Signaling
- Receptor phosphorylation recruits β-arrestin proteins
- β-arrestin-mediated signaling contributes to receptor function
- Internalization via β-arrestin-dependent mechanisms
Downstream Effects on Neurodegeneration
Expression Pattern in the Brain
ADORA3 exhibits a distinctive expression pattern in the central nervous system[@lu2016]:
Cellular Distribution
- [Neurons](/entities/neurons): High expression in hippocampal CA1-CA3 regions, cortical layers II-VI, and cerebellar Purkinje cells
- [Astrocytes](/entities/astrocytes): Moderate expression, particularly in regions adjacent to blood vessels
- [Microglia](/cell-types/microglia-neuroinflammation): High expression, especially in activated states
- Oligodendrocytes: Present but at lower levels
Regional Distribution
In the brain:
- Highest density: [Hippocampus](/brain-regions/hippocampus) (CA1-CA3, dentate gyrus), [cortex](/brain-regions/cortex) (prefrontal, parietal, temporal)
- Moderate: [Cerebellum](/brain-regions/cerebellum), [basal ganglia](/brain-regions/basal-ganglia), [thalamus](/brain-regions/thalamus)
- Lower: [Brainstem](/brain-regions/brainstem), [spinal cord](/brain-regions/spinal-cord)
This pattern of expression suggests roles in learning, memory, motor coordination, and neuroimmune modulation[@cunha2016].
Role in Neurodegenerative Diseases
Alzheimer's Disease
ADORA3 modulation has significant implications for AD pathogenesis[@huang2021][@yang2020]:
Amyloid-Beta Interactions
- A3AR activation reduces [Aβ](/proteins/amyloid-beta)-induced neuronal toxicity
- Agonists decrease Aβ production via γ-secretase modulation
- A3AR signaling enhances clearance of Aβ through autophagy
- Neuroinflammation reduction contributes to decreased Aβ accumulation
Tau Pathology
- A3AR activation attenuates tau hyperphosphorylation
- Reduction of tau aggregation through enhanced autophagy
- Protection against tau-induced synaptic dysfunction
- Modulation of GSK-3β activity (a key tau kinase)
Neuroinflammation
- Suppression of microglial activation
- Reduced pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6)
- Decreased NO and ROS production in glia
- Promotion of anti-inflammatory phenotype (M2 polarization)
Synaptic Protection
- Preservation of synaptic plasticity
- Enhancement of long-term potentiation (LTP)
- Protection against Aβ-induced synaptic loss
- Maintenance of dendritic spine density
Parkinson's Disease
ADORA3 represents a promising target for PD therapy[@li2022][@wang2021][@jacobson2017]:
Dopaminergic Neuron Protection
- A3AR agonists protect substantia nigra dopaminergic neurons
- Reduction of MPTP/6-OHDA-induced toxicity
- Enhancement of mitochondrial function
- Protection against α-synuclein toxicity
Neuroinflammation Modulation
- Suppression of microglial activation in substantia nigra
- Reduced dopaminergic neuron loss
- Decreased production of inflammatory mediators
- Promotion of microglial deactivation
Motor Function Improvement
- A3AR agonism improves motor performance in PD models
- Reduction of gait abnormalities
- Enhancement of spontaneous locomotion
- Potential for disease modification
Alpha-Synuclein Pathology
- A3AR activation reduces [alpha-synuclein](/proteins/alpha-synuclein) aggregation
- Enhanced clearance of α-synuclein aggregates
- Protection against α-synuclein-induced neurodegeneration
- Modulation of autophagy-lysosomal pathway
Other Neurodegenerative Conditions
Amyotrophic Lateral Sclerosis (ALS)
- A3AR agonism protects motor neurons
- Modulation of neuroinflammation
- Potential for combined therapeutic strategies
Huntington's Disease
- Protection against mutant huntingtin toxicity
- Enhancement of autophagy
- Reduced neuroinflammation
Multiple Sclerosis and Demyelinating Diseases
- A3AR agonists reduce demyelination
- Promotion of remyelination
- Suppression of autoimmune responses[@yu2023]
Ischemic Stroke
- A3AR activation provides neuroprotection
- Reduction of infarct size
- Improved functional recovery
- Anti-apoptotic effects
Therapeutic Strategies
Agonist-Based Approaches
Selective A3AR agonists have shown promise in preclinical and clinical settings[@muller2019][@baraldi2019]:
Clinical Candidates
Cl-IB-MECA: Most widely studied A3AR agonist
- Neuroprotective in multiple models
- Entered clinical trials for inflammatory conditions
- Favorable safety profile
IB-MECA: Earlier generation agonist
- Demonstrated efficacy in PD models
- Tested in clinical trials for hepatitis and asthma
N6-(3-iodobenzyl) derivatives: Newer optimized compounds
- Improved selectivity
- Enhanced brain penetration
- Better pharmacokinetic properties
Mechanisms of Action
- Direct neuroprotection via receptor activation
- Anti-inflammatory effects in the CNS
- Enhancement of neurotrophic factor production
- Promotion of neurogenesis
Antagonist-Based Strategies
While less explored, A3AR antagonists may have therapeutic potential[@fard2019]:
- May modulate adenosine tone in specific contexts
- Potential for combination therapies
- Utility in understanding receptor biology
Allosteric Modulation
Allosteric targeting offers advantages[@volpini2017]:
- Greater subtype selectivity possible
- More nuanced pharmacological effects
- Potential for biased signaling
- Reduced side effects
Clinical Development Status
Ongoing Clinical Trials
Several clinical trials are investigating A3AR-targeted therapies:
Challenges and Opportunities
Challenges[@yang2022]:
- Achieving adequate brain penetration
- Managing species differences in receptor pharmacology
- Balancing efficacy and side effects
- Long-term safety concerns
Opportunities:
- Disease modification potential
- Combination with other therapeutic strategies
- Personalized medicine approaches
- Novel delivery systems
Interacting Partners
Animal Models
- A3AR knockout mice: Available for mechanistic studies
- Conditional knockouts: For tissue-specific deletion
- Transgenic models: For overexpression studies
- Agonists: Cl-IB-MECA, IB-MECA, 2-Cl-Ado
- Antagonists: MRS1523, VUF5574, OT-7979
- Radioligands: [125I]AB-MECA for binding studies
- [Adenosine Signaling](/mechanisms/adenosine-signaling) - Purinergic signaling overview
- [Neuroprotection](/therapeutics/neuroprotection) - Cell survival mechanisms
- [Neuroinflammation](/mechanisms/neuroinflammation) - Brain inflammation
- [Autophagy](/entities/autophagy) - Cellular clearance
- [Neurotrophic Factors](/mechanisms/neurotrophic-factor-signaling) - Neuronal support
- [Alzheimer's Disease](/diseases/alzheimers-disease) - AD overview
- [Parkinson's Disease](/diseases/parkinsons-disease) - PD overview
- [Alpha-Synuclein](/proteins/alpha-synuclein) - PD protein
- [Amyloid Beta](/proteins/amyloid-beta) - AD protein
- [Tau](/proteins/tau) - AD protein
Future Directions
Emerging Research Areas
Biased signaling: Developing agonists that selectively activate beneficial pathways
Gene therapy: AAV-mediated A3AR overexpression
Cell-penetrant peptides: Targeted delivery strategies
Combination therapies: Synergistic approaches with other targets
Biomarkers: Identifying predictive markers for patient selectionUnmet Needs
- Brain-penetrant, selective A3AR agonists
- Long-term safety data in neurodegenerative populations
- Understanding of A3AR's complex signaling in different disease stages
- Optimal dosing and treatment regimens
See Also
- [Adenosine Signaling](/mechanisms/adenosine-signaling) - Complete purinergic signaling pathway
- [Neuroprotection](/therapeutics/neuroprotection) - Neuroprotective strategies
- [Neuroinflammation](/mechanisms/neuroinflammation) - Neuroinflammatory mechanisms
- [Parkinson's Disease](/diseases/parkinsons-disease) - PD comprehensive overview
- [Alzheimer's Disease](/diseases/alzheimers-disease) - AD comprehensive overview
- [GPCR Drug Targets](/mechanisms/gpcr-neurodegeneration) - GPCRs in neurodegeneration
- [Purinergic Signaling](/mechanisms/purinergic-signaling) - ATP and adenosine signaling
External Links
- [NCBI Gene - ADORA3](https://www.ncbi.nlm.nih.gov/gene/128)
- [UniProt - P0DP23](https://www.uniprot.org/uniprot/P0DP23)
- [Ensembl - ENSG00000121879](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121879)
- [IUPHAR/BPS Guide to Pharmacology - A3 adenosine receptor](https://www.guidetopharmacology.org/GRAC/ObjectDetailsForward?objectId=18)
References
[Fredholm BB et al, International Union of Pharmacology: adenosine receptors (2001)](https://pubmed.ncbi.nlm.nih.gov/9384485/)
[Borea PA et al, The A3 adenosine receptor: history and perspectives (2015)](https://pubmed.ncbi.nlm.nih.gov/25593237/)
[Chen JF et al, Adenosine receptors as drug targets—what are the challenges? (2013)](https://pubmed.ncbi.nlm.nih.gov/23493010/)
[Gessi S et al, Adenosine receptors in neurodegenerative disorders (2016)](https://pubmed.ncbi.nlm.nih.gov/27241159/)
[Cunha RA, How does adenosine control neuronal dysfunction and neurodegeneration? (2016)](https://pubmed.ncbi.nlm.nih.gov/26771864/)
[Bours MJ et al, P2X7 and P2Y receptors as regulators of ATP-induced inflammation (2011)](https://pubmed.ncbi.nlm.nih.gov/21443483/)
[Lu Y et al, Expression and distribution of adenosine A3 receptor in rat brain (2016)](https://pubmed.ncbi.nlm.nih.gov/26867610/)
[Huang L et al, A3 adenosine receptor activation ameliorates neuronal death (2021)](https://pubmed.ncbi.nlm.nih.gov/34547821/)
[Yang H et al, A3 adenosine receptor agonism promotes neurogenesis in AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32812234/)
[Li X et al, Targeting adenosine A3 receptor for Parkinson's disease therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35051654/)
[Wang J et al, A3 adenosine receptor agonist protects dopaminergic neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/33834488/)
[Müller CE et al, A3 adenosine receptor agonists: patent review 2009-2018 (2019)](https://pubmed.ncbi.nlm.nih.gov/30632347/)
[Jacobson KA et al, Adenosine A3 receptor as a novel target for PD (2017)](https://pubmed.ncbi.nlm.nih.gov/28345644/)
[Stockwell J et al, Adenosine A1 and A3 receptors in the brain (2017)](https://pubmed.ncbi.nlm.nih.gov/28449782/)
[Yu L et al, A3 adenosine receptor agonists attenuate neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/36758792/)
[Chen X et al, Role of adenosine signaling in microglial activation (2021)](https://pubmed.ncbi.nlm.nih.gov/34289123/)
[Fard SG et al, Selective A3 adenosine receptor agonists and antagonists (2019)](https://pubmed.ncbi.nlm.nih.gov/31757254/)
[Volpini R et al, Structure-activity relationships at adenosine receptors (2017)](https://pubmed.ncbi.nlm.nih.gov/28284567/)
[Baraldi PG et al, A3 adenosine receptor agonists: from lead optimization (2019)](https://pubmed.ncbi.nlm.nih.gov/31268055/)
[Khalili M et al, Adenosine A3 receptor in cell-based therapies for PD (2021)](https://pubmed.ncbi.nlm.nih.gov/33738544/)
[Yang L et al, Emerging therapeutic strategies targeting adenosine receptors (2022)](https://pubmed.ncbi.nlm.nih.gov/35041956/)